Kazuaki Jindai1,2,3, Courtney Crawford1, Ann R Thomas1. 1. 1 Oregon Public Health Division, Acute and Communicable Disease Prevention, Oregon Health Authority, Portland, OR, USA. 2. 2 Veterans Affairs Portland Healthcare System, Portland, OR, USA. 3. 3 School of Public Health, Oregon Health & Science University, Portland, OR, USA.
Abstract
OBJECTIVES: Given the known high morbidity and mortality of hepatitis C virus (HCV) infection in Oregon, we sought to develop a practical method of estimating the severe sequelae of HCV infection among Medicaid beneficiaries in Oregon. METHODS: We assembled a retrospective cohort that identified all Oregon Medicaid beneficiaries with HCV infection enrolled for at least 1 year during 2009-2013. We linked this cohort to 3 data sets to identify HCV-related deaths, cases of hepatocellular carcinoma (HCC), and first hospitalizations for advanced liver disease (ALD). We calculated incidence density rates and used multivariable Cox regression modeling to calculate adjusted hazard ratios (aHRs) to evaluate the association between demographic characteristics (birth year, sex, race, ethnicity) and these 3 outcomes. RESULTS: Of 11 790 Oregon Medicaid beneficiaries with HCV infection, 474 (4.0%) had an HCV-related death, 156 (1.3%) had HCC, and 596 (5.1%) had a first hospitalization for ALD. Adjusted hazard ratios for deaths were 2.2 (95% confidence interval [CI], 1.6-2.8) among persons born in 1945 through 1965 (vs persons born after 1965), 2.1 (95% CI, 1.7-2.5) among males (vs females), and 1.9 (95% CI, 1.2-2.9) among Asian/Pacific Islanders and 2.2 (95% CI, 1.5-3.2) among American Indian/Alaska Natives (vs white persons). The same risk groups had significant aHRs for first hospitalizations for ALD. Persons born before 1945 (aHR = 17.0; 95% CI, 5.2-55.8) and in 1945 through 1965 (aHR = 12.8; 95% CI, 4.1-40.3) vs born after 1965, males (aHR = 3.3; 95% CI, 2.3-4.8) vs females, and Asian/Pacific Islanders (aHR = 3.9; 95% CI, 2.3-6.7) vs white persons had higher risks for HCC. CONCLUSIONS: Continued assessments using the methods piloted in this study will allow Oregon to monitor trends in severe sequelae of HCV infection over time.
OBJECTIVES: Given the known high morbidity and mortality of hepatitis C virus (HCV) infection in Oregon, we sought to develop a practical method of estimating the severe sequelae of HCV infection among Medicaid beneficiaries in Oregon. METHODS: We assembled a retrospective cohort that identified all Oregon Medicaid beneficiaries with HCV infection enrolled for at least 1 year during 2009-2013. We linked this cohort to 3 data sets to identify HCV-related deaths, cases of hepatocellular carcinoma (HCC), and first hospitalizations for advanced liver disease (ALD). We calculated incidence density rates and used multivariable Cox regression modeling to calculate adjusted hazard ratios (aHRs) to evaluate the association between demographic characteristics (birth year, sex, race, ethnicity) and these 3 outcomes. RESULTS: Of 11 790 Oregon Medicaid beneficiaries with HCV infection, 474 (4.0%) had an HCV-related death, 156 (1.3%) had HCC, and 596 (5.1%) had a first hospitalization for ALD. Adjusted hazard ratios for deaths were 2.2 (95% confidence interval [CI], 1.6-2.8) among persons born in 1945 through 1965 (vs persons born after 1965), 2.1 (95% CI, 1.7-2.5) among males (vs females), and 1.9 (95% CI, 1.2-2.9) among Asian/Pacific Islanders and 2.2 (95% CI, 1.5-3.2) among American Indian/Alaska Natives (vs white persons). The same risk groups had significant aHRs for first hospitalizations for ALD. Persons born before 1945 (aHR = 17.0; 95% CI, 5.2-55.8) and in 1945 through 1965 (aHR = 12.8; 95% CI, 4.1-40.3) vs born after 1965, males (aHR = 3.3; 95% CI, 2.3-4.8) vs females, and Asian/Pacific Islanders (aHR = 3.9; 95% CI, 2.3-6.7) vs white persons had higher risks for HCC. CONCLUSIONS: Continued assessments using the methods piloted in this study will allow Oregon to monitor trends in severe sequelae of HCV infection over time.
Entities:
Keywords:
hepatitis C infection; hepatocellular carcinoma; morbidity; mortality; state-specific epidemiology
Authors: Anne C Moorman; Stuart C Gordon; Loralee B Rupp; Philip R Spradling; Eyasu H Teshale; Mei Lu; David R Nerenz; Cynthia C Nakasato; Joseph A Boscarino; Emily M Henkle; Nancy J Oja-Tebbe; Jian Xing; John W Ward; Scott D Holmberg Journal: Clin Infect Dis Date: 2012-09-18 Impact factor: 9.079
Authors: Mahendra S Nehra; Ying Ma; Christopher Clark; Ruben Amarasingham; Don C Rockey; Amit G Singal Journal: J Clin Gastroenterol Date: 2013 May-Jun Impact factor: 3.062
Authors: Alexander Monto; Keyur Patel; Alan Bostrom; Stephen Pianko; Paul Pockros; John G McHutchison; Teresa L Wright Journal: Hepatology Date: 2004-03 Impact factor: 17.425
Authors: Eli S Rosenberg; Eric W Hall; Patrick S Sullivan; Travis H Sanchez; Kimberly A Workowski; John W Ward; Deborah Holtzman Journal: Clin Infect Dis Date: 2017-06-01 Impact factor: 9.079